RJA
CPIX icon

Raymond James & Associates’s Cumberland Pharmaceuticals CPIX Stock Holding History

Raymond James & Associates’s Portfolio CPIX Stock Details CPIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-47,366
Closed -$242K – 1914
2013
Q2 		$242K Buy
+47,366
New +$236K ﹤0.01% 1790

Other funds holding CPIX

AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
KIM
Kestrel Investment Management San Mateo, California $167M AUM 20.81% 1-Year Est. Return
UCFA
United Capital Financial Advisors Irving, Texas $16.3B AUM 16.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BG
BlackRock Group London, United Kingdom $210B AUM 15.5% 1-Year Est. Return
PCM
Perritt Capital Management Chicago, Illinois $59.8M AUM 26.94% 1-Year Est. Return

Raymond James & Associates's CPIX Position: Q3 2013 in Review

Raymond James & Associates sold out of Cumberland Pharmaceuticals (CPIX) in Q3 2013, closing a stake of 47,366 shares — an estimated $242K sold.

Raymond James & Associates first reported a position in CPIX in Q2 2013 and held it in 1 quarter. The position peaked at $242K in Q2 2013. 45 funds tracked by Wall St. Rank hold CPIX as of Q3 2013.

  • Raymond James & Associates reported no remaining Cumberland Pharmaceuticals position as of Q3 2013 after selling out during the quarter.
  • Raymond James & Associates sold 47,366 Cumberland Pharmaceuticals shares in Q3 2013, an estimated $242K.
  • Raymond James & Associates first reported a position in Cumberland Pharmaceuticals in Q2 2013 and held it in 1 quarter.
  • Raymond James & Associates's Cumberland Pharmaceuticals position peaked at $242K in Q2 2013.
  • 45 funds tracked by Wall St. Rank held Cumberland Pharmaceuticals as of Q3 2013.

Based on Raymond James & Associates's 13F filing for Q3 2013, filed 13 Nov 2013.